Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 21:00:00 17/06/2024 BST			5-day change	1st Jan Change
4.75 ^USD	-1.04%		+5.79%	+30.49%

05-29	MannKind Agrees to Cross License Deal With Pulmatrix	MT
05-29	Pulmatrix, Inc. Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

MannKind Corporation - Inhale-3 Study Results to be presented during a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions	06-06	AQ
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions	06-05	AQ
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation	05-30	AQ
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix	05-29	AQ
MannKind : First Quarter 2024 Earnings Call Presentation	05-09	PU
MannKind: Q1 Earnings Snapshot	05-08	AQ
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update	05-08	AQ
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease	05-06	AQ
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024	05-01	AQ
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases	04-30	AQ
MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease	04-29	AQ
MannKind Repays Certain Debt Obligations	04-03	AQ
MannKind Announces CFO Transition	03-26	AQ
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	03-11	AQ
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	03-05	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	03-04	AQ
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	02-27	AQ
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	02-20	AQ
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	02-15	AQ
MannKind Announces Up To $200 Million Royalty Purchase Agreement With Sagard Healthcare	01-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Press Releases

Filters